Gut Bacteria Metabolite Fuels Pre-Leukemic Cell Growth via ALPK1 Receptor
A microbial sugar molecule leaking from an aging gut selectively expands pre-leukemic blood stem cells, revealing a new therapeutic target.
Summary
Researchers discovered that ADP-heptose, a metabolite produced exclusively by Gram-negative gut bacteria, accumulates in the bloodstream of older individuals due to age-related intestinal barrier dysfunction. This circulating molecule binds the intracellular receptor ALPK1 in DNMT3A-mutant hematopoietic stem cells, triggering NF-κB activation and transcriptional reprogramming that gives pre-leukemic cells a competitive proliferative advantage. Using mouse models with intestinal injury, fecal microbiota transplants from aged donors, and human blood samples, the team demonstrated that blocking the ADP-heptose–ALPK1 axis reduces clonal expansion. The findings establish a direct mechanistic link between gut aging and clonal hematopoiesis of indeterminate potential (CHIP), suggesting this pathway is a promising drug target for preventing progression to leukemia and inflammatory cardiovascular disease.
Detailed Summary
Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the gradual expansion of mutation-carrying blood stem cells, predominantly bearing loss-of-function mutations in epigenetic regulators such as DNMT3A, TET2, and ASXL1. CHIP prevalence rises sharply with age, and larger clone sizes predict progression to myelodysplastic syndromes, acute myeloid leukemia, and immune-mediated conditions including coronary artery disease. Despite these associations, the environmental triggers that accelerate pre-leukemic cell expansion during normal aging remained poorly defined, particularly for DNMT3A-mutant CHIP.
This study investigated whether age-associated gut barrier dysfunction acts as an upstream driver of DNMT3A-mutant HSC expansion. Using competitive bone marrow transplant models in mice, the authors showed that high-dose radiation (damaging the intestinal epithelium) but not low-dose radiation (sparing it) enabled expansion of Dnmt3a−/− HSCs. Direct intestinal injury with dextran sulfate sodium (DSS) replicated this effect, and broad-spectrum antibiotic treatment abolished the DSS-driven expansion, implicating gut microbiota. Fecal microbiota transplantation from DSS-treated or aged donor mice into chimeric hosts carrying Dnmt3a-mutant cells recapitulated HSC expansion, confirming that the dysbiotic microbial community itself, rather than direct epithelial damage, is the proximate driver.
Mechanistically, the team identified ADP-D-glycero-β-D-manno-heptose (ADP-heptose), a biosynthetic intermediate of LPS production found exclusively in Gram-negative bacteria, as the key circulating effector. ADP-heptose levels were elevated in the blood of aged mice and, critically, in plasma from older humans. ADP-heptose binds to the cytosolic innate immune receptor ALPK1, which in pre-leukemic cells triggers NF-κB-driven transcriptional reprogramming. Unlike wild-type HSCs, DNMT3A-mutant cells exhibited exaggerated and sustained ALPK1-NF-κB signaling, translating microbial exposure into a selective proliferative advantage. Genetic deletion of ALPK1 or pharmacological inhibition of the pathway blunted ADP-heptose-driven clonal expansion in vitro and in vivo. The metabolite also correlated with elevated inflammatory markers and cardiovascular risk signatures in human CHIP carriers.
These findings place the ADP-heptose–ALPK1 axis at the mechanistic intersection of gut aging, microbial translocation, and pre-leukemic clonal dynamics. They suggest that therapeutic strategies targeting ALPK1, or reducing systemic ADP-heptose through microbiome modulation, could slow CHIP progression and lower the associated risk of leukemia and cardiovascular disease. The study also implies that monitoring circulating ADP-heptose levels may serve as a biomarker for CHIP progression risk in older adults.
Key Findings
- ADP-heptose, a Gram-negative bacterial metabolite, is uniquely elevated in blood of older individuals and aged mice.
- Intestinal barrier injury or aged-donor fecal transplants selectively expand DNMT3A-mutant HSCs in mouse models.
- ADP-heptose binds ALPK1 in pre-leukemic cells, activating NF-κB and conferring a clonal proliferative advantage.
- Broad-spectrum antibiotics and ALPK1 deletion each abolish gut-dysfunction-driven pre-leukemic HSC expansion.
- Circulating ADP-heptose correlates with increased inflammation and cardiovascular risk markers in human CHIP carriers.
Methodology
The study combined competitive bone marrow transplant models in mice (using low- vs high-dose radiation conditioning and DSS-induced colitis), 16S rRNA quantification, fecal microbiota transplantation from young/old donors, mass-spectrometry-based ADP-heptose quantification in mouse and human plasma, and ALPK1 genetic/pharmacological perturbation experiments in vitro and in vivo.
Study Limitations
The majority of mechanistic work was performed in mouse models, and causal human evidence is associative; the study focused on DNMT3A-mutant CHIP, leaving open whether TET2 or ASXL1 mutations respond similarly to ADP-heptose. Long-term safety and specificity of ALPK1 inhibition in humans have not yet been evaluated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.